Status:
COMPLETED
Indicated Prevention of Psychotic Disorders With Low-dose Lithium
Lead Sponsor:
Melbourne Health
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Schizophrenia
Bipolar Disorder
Eligibility:
All Genders
15-30 years
Phase:
PHASE4
Brief Summary
This study investigates the neuroprotective properties of low-dose lithium in young individuals at ultra-high risk of developping a first psychotic episode. Fourty individuals having some symptoms of ...
Detailed Description
To investigate whether low-dose lithium is an effective agent in indicated prevention amongst subjects at ultra-high risk of developing a psychotic disorder. This aim will be achieved by treating a hi...
Eligibility Criteria
Inclusion
- Attenuated psychotic symptoms
- Self-limited brief psychotic episode
- Family History of psychosis and decrease in functioning over last year
Exclusion
- Organic causes of subthreshold psychotic symptoms (eg. epilepsy)
- More than one week of neuroleptic treatment
Key Trial Info
Start Date :
November 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00202306
Start Date
November 1 2001
End Date
December 1 2006
Last Update
May 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ORYGEN Youth Health, PACE Clinic
Parkville, Victoria, Australia, 3052